Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma.

Molecular oncology - 1 Nov 2025

Manasterski Piotr J, Danks Molly R, Thomson John P, Muir Morwenna, Lee Martin, Dawson John C, Amaral Ana T, Diaz-Martin Juan, Moura David S, Martin-Broto Javier, Alsaadi Ali, Salter Donald M, Oswald Ailsa J, Grimes Graeme, Hayward Larry, Hupp Ted R, Sisley Karen, Huang Paul H, Carragher Neil O, Brunton Valerie G

Abstract excerpt

Undifferentiated pleomorphic sarcoma (UPS) is a rare cancer with limited systemic treatment options and poor outcomes. To seek novel therapeutic interventions, we undertook mutational analysis of 20 UPS patient tumours, four established UPS cell lines and three patient-derived xenograft (PDX) models. Frequently mutated genes were uncommon; in contrast, copy number (CN) events were common with CN gain frequently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Genomics

Share to Pyridones

Share to Pyrimidinones

Share to Sarcoma

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40415599
DOI: 10.1002/1878-0261.70059
PMCID: PMC12591313

Genes

CDK6
EGFR
JUN
PTEN
RB1
WNT8B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma.PMID 40415599Read ↗

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Semantic proximity Read ↗

Heterogeneity of Undifferentiated Pleomorphic Sarcoma Genetic Landscape: Is There a Room for Targeted Therapy?Semantic proximity Read ↗

The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities.Semantic proximity Read ↗

Single-cell sequencing reveals the landscape of the tumor microenvironment in a skeletal undifferentiated pleomorphic sarcoma patientSemantic proximity Read ↗

Emerging target discovery and drug repurposing opportunities in chordomaSemantic proximity Read ↗

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.Semantic proximity Read ↗

Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of boneSemantic proximity Read ↗

Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profileSemantic proximity Read ↗

From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipelineSemantic proximity Read ↗

Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.Semantic proximity Read ↗

Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation SequencingSemantic proximity Read ↗

Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.